Instrument Inactif

Communiqués GreenLight Biosciences Holdings

Actions

GRNA

US39536G1058

Recherche biotechnologique et médicale

Communiqués

28/06/24	GreenLight Biosciences features in Science Magazine: Does RNA make the Perfect Pesticide	PU
24/07/23	GreenLight Announces Completion of Merger with Fall Line Endurance Fund	GL
20/07/23	GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares	GL
30/05/23	GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction	GL
11/05/23	GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress	GL
12/04/23	GreenLight Biosciences Releases Inaugural Sustainability Report	GL
30/03/23	GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line	GL
28/03/23	GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results	GL
09/03/23	GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day	GL
01/03/23	GreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development Strategy	GL
01/03/23	GreenLight Biosciences : to Host R&D Day Series on Plant and Human Health Development Strategy	PU
01/02/23	GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate	GL
09/01/23	GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines	GL
09/11/22	GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress	GL
07/11/22	GreenLight Biosciences to Participate in Upcoming Investor Conferences in November	GL
12/10/22	GreenLight Biosciences : Costs Associated with Exit/Disposal - Form 8-K	PU
12/10/22	GreenLight Biosciences announces realignment to focus on near-term value drivers	GL
05/10/22	GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA	GL
26/09/22	GreenLight Biosciences : INDEX TO FINANCIAL STATEMENTS - Form 8-K	PU
16/08/22	GreenLight Biosciences : Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Form 8-K	PU
15/08/22	GreenLight Biosciences : August investor presentation	PU
15/08/22	GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress	GL
12/08/22	GreenLight Biosciences announces $109 million financing	GL
01/08/22	GreenLight Biosciences : and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine - Form 8-K	PU
01/08/22	GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine	GL